Treatment of 22Q11.2 deletion syndrome with cannabidiol
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject.
1. A method of treating one or more behavioral symptoms of 22q11.2 deletion syndrome in a subject, the method comprising:
administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject.
2. The method of claim 1 , wherein the behavioral symptom that is alleviated is general anxiety.
3. The method of claim 1 , wherein the CBD is (−)-CBD.
4. The method of claim 1 , wherein the effective amount of CBD is between about 50 mg and about 1000 mg total daily.
5. The method of claim 1 , wherein the CBD is formulated as a gel.
6. The method of claim 5 , wherein the CBD is formulated as a permeation-enhanced gel.
7. The method of claim 1 , wherein the CBD is administered in a single daily dose.
8. The method of claim 1 , wherein the CBD is administered in two daily doses.
9. The method of claim 1 , wherein the CBD is transdermally administered on the subject's arm.
10. The method of claim 1 , wherein the CBD is a synthetic CBD.
11. The method of claim 1 , wherein the CBD is botanically derived.
12. The method of claim 1 , wherein the CBD is purified.
13. The method of claim 1 , wherein administering comprises transdermally administering.
14. The method of claim 13 , wherein transdermally administering an effective amount of cannabidiol (CBD) reduces an intensity of at least one adverse event relative to orally administering CBD.
15. The method of claim 14 , wherein the at least one adverse event is selected from the group consisting of somnolence, psychoactive effects, liver function, and GI related adverse events.